Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
- The FDA has instituted a partial clinical hold on Aprea Therapeutics Inc's (NASDAQ:APRE) clinical trials of eprenetapopt (APR-246) combined with azacitidine in its myeloid malignancy programs.
- Approximately 20 patients currently receiving eprenetapopt in combination with azacitidine in the Company's myeloid malignancy programs, including the MDS, AML, and post-transplant maintenance trials, all of which have completed enrollment.
- Patients who are benefiting from treatment can continue to receive study treatment. As part of the clinical hold, no additional patients can be enrolled in these trials.
- Aprea intends to work closely with the FDA to analyze the data, address the specific questions raised, and seek to resolve the partial clinical hold as soon as possible.
- The Company will host a webcast conference call today at 8:30 AM E.T.
- Price Action: APRE shares are down 8.14% at $3.95 during the premarket session on the last check Friday.
- Related content: Benzinga's Full FDA Calendar.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!